|
|||
2008-11-12 13:17:14 CET 2008-11-12 13:17:14 CET REGULATED INFORMATION Inion Oyj - Company AnnouncementPayment of Non-Executive Directors’ Fees in SharesInion Oy (“Inion or “the Company”) Payment of Non-Executive Directors' Fees in Shares Tampere, Finland and Guildford, UK. 12 November 2008…Inion [LSE: IIN.L], a company focused on the development of novel biodegradable medical implants, announces that its Non-Executive Directors have received Inion shares in lieu of 50% of their directors' fees in respect of the quarter ended 30 September 2008. This is part of a share-based payment scheme previously announced on 8 October 2007. The share price used to calculate the number of shares issued to each Director was 8.75p, representing the closing mid-market share price on 30 September 2008, the last working day of the third quarter of 2008. Non-Executive No. of ordinary Share price Total % of current shareholding Director shares of EUR (p) following issued share issue 0.03 issued capital 1 Ian Paling 38,043 8.75p 40,128 0.05 David 42,857 8.75p 126,578 0.17 Anderson Jim Beery 46,429 8.75p 137,127 0.18 Peter Jensen 50,000 8.75p 147,674 0.19 Markku Silén 46,429 8.75p 137,127 0.18 1 This includes 2,085 shares which are held by Mr Paling as Trustee for the beneficial ownership of connected persons. -Ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / Helena Galilee / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima™ family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. |
|||
|